MARTINSRIED (dpa-AFX) - Medigene AG (MDGEF.PK), a German bio-technology firm, on Wednesday reported a surge in revenue for 2022, mainly due to a comprehensive TCR-T and technology partnership with BioNTech as well as a $3 million milestone payment received from 2seventy bio.
For the 12-month period, the Munich-headquartered company recorded a revenue of 31.3 million euros, compared with 10.5 million euros in 2021.
Looking ahead, Selwyn Ho, CEO of Medigene, said: 'In 2023, we continue to progress our own MDG1015 program towards a first-in-human clinical trial and look forward to selecting our first lead candidate from the MDG10xx program in the second half of this year....'
Copyright(c) 2023 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2023 AFX News
